Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2017-09-05 Regulatory Filings
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Antifibrotic LOXL2 Program Clears Preclinical Development 2 pages 127.6KB
Regulatory Filings Classification · 95% confidence The document is a media release dated 6 September 2017 from Pharmaxis Ltd announcing the completion of preclinical development of their anti-fibrotic LOXL2 program and the commencement of phase 1 clinical trials. It discusses the drug development pipeline, market potential, and future plans. There are no financial statements, regulatory filings, or detailed financial data. The content is a corporate announcement about a product development milestone rather than a financial report, regulatory filing, or management discussion. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a press release about a scientific and clinical development update, which aligns best with a general Regulatory Filings (RNS) category as a miscellaneous announcement that does not fit other specific categories.
2017-09-05 English
Appendix 3B - Exercise of Employee Options 11 pages 134.6KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including the class of securities, number issued, terms, issue price, purpose, and application for quotation on the ASX. It references specific ASX rules and includes a quotation agreement. The content is focused on announcing and providing details about a new share issue and the application for quotation of these additional securities. There are no financial statements, management discussion, or audit information present. The document is a formal announcement related to capital changes, specifically new share issuance and quotation application, which aligns with the category for announcements regarding new share issues or capital changes.
2017-08-31 English
Pharmaxis Investor Presentation 29 pages 1.5MB
Investor Presentation Classification · 95% confidence The document is a detailed corporate presentation or overview of Pharmaxis, including forward-looking statements, company overview, pipeline details, management bios, shareholder information, and key business deals. It contains no financial statements, no audit opinions, no voting results, no legal proceedings, no earnings highlights, and no regulatory certifications. The content is focused on business strategy, product pipeline, partnerships, and management profiles, typical of an Investor Presentation. The length is substantial (15,000 characters), and it is not a brief announcement or a report publication notice. Therefore, the document best fits the category of an Investor Presentation (IP).
2017-08-29 English
Change in substantial holding 3 pages 227.1KB
Regulatory Filings
2017-08-29 English
Change in substantial holding 4 pages 130.9KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 Notice of change of interests of substantial holder under the Corporations Act 2001 Section 671B. It details changes in voting power and relevant interests of a substantial shareholder (Allan Gray Australia Pty Ltd) in Pharmaxis Ltd. The content includes tables of related bodies corporate, funds managed, changes in relevant interests, and present relevant interests. This type of filing is a notification of changes in significant share ownership levels, which corresponds to the category Major Shareholding Notification (MRQ). The document is substantive and not merely an announcement or certification, and it does not fit other categories such as director dealings or capital changes. Therefore, the correct classification is MRQ with high confidence.
2017-08-28 English
Boehringer Ingelheim Initiates Phase IIa Study in NASH 2 pages 118.9KB
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the initiation of a Phase IIa clinical study by Boehringer Ingelheim for a drug candidate acquired from Pharmaxis. It discusses the study design, objectives, and milestone payments related to the drug development. There are no financial statements, regulatory filings, or detailed financial performance data. The content focuses on a clinical trial update and partnership milestone payment, which is typical of a Capital/Financing Update or a clinical development progress announcement. It is not an Annual Report, Earnings Release, or any other financial report. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length and content support this classification with high confidence.
2017-08-24 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.